Tara C. Marcink

Tara C. Marcink

Auto-generated profile, based on publicly available information

Tara C. Marcink

Columbia University Vagelos College of Physicians & Surgeons

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2019 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
ANAnthony H. Nguyen
Anthony H. Nguyen
ATAlex Thomsen
Alex Thomsen
TCThomas J. Cahill
Thomas J. Cahill
RHRick Huang
Rick Huang
LHLi-Yin Huang
Li-Yin Huang
RLRobert J. Lefkowitz
Robert J. Lefkowitz

19 August 2022 in Science Advances
Verified
Journal Article
Open access
TMTara C. Marcink
Tara C. Marcink
TKThomas Kicmal
Thomas Kicmal
EAEmily Armbruster
Emily Armbruster
ZZZhening Zhang
Zhening Zhang
GZGillian Zipursky
Gillian Zipursky
AMAnne Moscona
Anne Moscona
SARS-CoV-2 cell entry is completed after viral spike (S) protein–mediated membrane fusion between viral and host cell membranes. Stable prefusion and postfusion S structures have been resolved by cryo–electron microscopy and cryo–electron tomography, but the refolding intermediates on the fusion pathway are transient and have not been examined. We used an antiviral lipopeptide entry inhibitor to arrest S protein refolding and thereby capture intermediates as S proteins interact with hACE2 and fusion-activating proteases on cell-derived target membranes. Cryo–electron tomography imaged both extended and partially folded intermediate states of S2, as well as a novel late-stage conformation on the pathway to membrane fusion. The intermediates now identified in this dynamic S protein–directed fusion provide mechanistic insights that may guide the design of CoV entry inhibitors.

10 February 2023 in Science Advances
Verified
Journal Article
Closed access
TMTara C. Marcink
Tara C. Marcink
GZGillian Zipursky
Gillian Zipursky
WCWenjing Cheng
Wenjing Cheng
KSKyle Stearns
Kyle Stearns
SSShari Stenglein
Shari Stenglein
AMAnne Moscona
Anne Moscona
Paramyxoviruses—including important pathogens like parainfluenza, measles, and Nipah viruses—use a receptor binding protein [hemagglutinin-neuraminidase (HN) for parainfluenza] and a fusion protein (F), acting in a complex, to enter cells. We use cryo–electron tomography to visualize the fusion complex of human parainfluenza virus 3 (HN/F) on the surface of authentic clinical viruses at a subnanometer resolution sufficient to answer mechanistic questions. An HN loop inserts in a pocket on F, showing how the fusion complex remains in a ready but quiescent state until activation. The globular HN heads are rotated with respect to each other: one downward to contact F, and the other upward to grapple cellular receptors, demonstrating how HN/F performs distinct steps before F activation. This depiction of viral fusion illuminates potentially druggable targets for paramyxoviruses and sheds light on fusion processes that underpin wide-ranging biological processes but have not been visualized in situ or at the present resolution.

28 June 2024 in Science
Verified
Journal Article
Closed access
DZDawid S Zyla
Dawid S Zyla
RMRoberta Della Marca
Roberta Della Marca
GNGele Niemeyer
Gele Niemeyer
GZGillian Zipursky
Gillian Zipursky
KSKyle Stearns
Kyle Stearns
ESErica Ollmann Saphire
Erica Ollmann Saphire
Measles virus (MeV) presents a public health threat that is escalating as vaccine coverage in the general population declines and as populations of immunocompromised individuals, who cannot be vaccinated, increase. There are no approved therapeutics for MeV. Neutralizing antibodies targeting viral fusion are one potential therapeutic approach but have not yet been structurally characterized or advanced to clinical use. We present cryo–electron microscopy (cryo-EM) structures of prefusion F alone [2.1-angstrom (Å) resolution], F complexed with a fusion-inhibitory peptide (2.3-Å resolution), F complexed with the neutralizing and protective monoclonal antibody (mAb) 77 (2.6-Å resolution), and an additional structure of postfusion F (2.7-Å resolution). In vitro assays and examination of additional EM classes show that mAb 77 binds prefusion F, arrests F in an intermediate state, and prevents transition to the postfusion conformation. These structures shed light on antibody-mediated neutralization that involves arrest of fusion proteins in an intermediate state.

1 December 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AGAlexander L. Greninger
Alexander L. Greninger
KRKsenia Rybkina
Ksenia Rybkina
MLMichelle J. Lin
Michelle J. Lin
JDJennifer Drew-Bear
Jennifer Drew-Bear
TMTara C. Marcink
Tara C. Marcink
AMAnne Moscona
Anne Moscona
The capacity of respiratory viruses to undergo evolution within the respiratory tract raises the possibility of evolution under the selective pressure of the host environment or drug treatment. Long-term infections in immunocompromised hosts are potential drivers of viral evolution and development of infectious variants. We showed that intrahost evolution in chronic human parainfluenza virus 3 (HPIV3) infection in immunocompromised individuals elicited mutations that favored viral entry and persistence, suggesting that similar processes may operate across enveloped respiratory viruses. We profiled longitudinal HPIV3 infections from 2 immunocompromised individuals that persisted for 278 and 98 days. Mutations accrued in the HPIV3 attachment protein hemagglutinin-neuraminidase (HN), including the first in vivo mutation in HN’s receptor binding site responsible for activating the viral fusion process. Fixation of this mutation was associated with exposure to a drug that cleaves host-cell sialic acid moieties. Longitudinal adaptation of HN was associated with features that promote viral entry and persistence in cells, including greater avidity for sialic acid and more active fusion activity in vitro, but not with antibody escape. Long-term infection thus led to mutations promoting viral persistence, suggesting that host-directed therapeutics may support the evolution of viruses that alter their biophysical characteristics to persist in the face of these agents in vivo.

21 September 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
TMTara C. Marcink
Tara C. Marcink
TWTong Wang
Tong Wang
AGAmedee des Georges
Amedee des Georges
MPMatteo Porotto
Matteo Porotto
AMAnne Moscona
Anne Moscona
Infection by human parainfluenza viruses (HPIVs) causes widespread lower respiratory diseases, including croup, bronchiolitis, and pneumonia, and there are no vaccines or effective treatments for these viruses. HPIV3 is a member of the Respirovirus species of the Paramyxoviridae family. These viruses are pleomorphic, enveloped viruses with genomes composed of single-stranded negative-sense RNA. During viral entry, the first step of infection, the viral fusion complex, comprised of the receptor-binding glycoprotein hemagglutinin-neuraminidase (HN) and the fusion glycoprotein (F), mediates fusion upon receptor binding. The HPIV3 transmembrane protein HN, like the receptor-binding proteins of other related viruses that enter host cells using membrane fusion, binds to a receptor molecule on the host cell plasma membrane, which triggers the F glycoprotein to undergo major conformational rearrangements, promoting viral entry. Subsequent fusion of the viral and host membranes allows delivery of the viral genetic material into the host cell. The intermediate states in viral entry are transient and thermodynamically unstable, making it impossible to understand these transitions using standard methods, yet understanding these transition states is important for expanding our knowledge of the viral entry process. In this study, we use cryo-electron tomography (cryo-ET) to dissect the stepwise process by which the receptor-binding protein triggers F-mediated fusion, when forming a complex with receptor-bearing membranes. Using an on-grid antibody capture method that facilitates examination of fresh, biologically active strains of virus directly from supernatant fluids and a series of biological tools that permit the capture of intermediate states in the fusion process, we visualize the series of events that occur when a pristine, authentic viral particle interacts with target receptors and proceeds from the viral entry steps of receptor engagement to membrane fusion. Human respiratory parainfluenza viruses (HPIVs) cause the majority of childhood cases of croup, bronchiolitis, and pneumonia. HPIV3, like most other paramyxoviruses, uses two specialized proteins to mediate cell entry: the fusion protein (F) and the receptor-binding protein, hemagglutinin-neuraminidase (HN). F is only activated to mediate membrane fusion during entry when it is triggered by a signal from the separate receptor-binding molecule, HN–a mechanism first elucidated for HPIV3 and later extended to this entire group of human pathogenic viruses. These two distinct membrane glycoproteins work in synchrony as a molecular machine, exquisitely tuned to enter the right cells at the right time. Much has been learned about the functional sites on the receptor-binding and F molecules for this group of viruses, and mechanisms have been proposed to explain molecular, biochemical, and crystal structure data. But the key intermediate steps, from receptor binding to membrane fusion, are fleeting and unstable. Furthermore, it is unclear how HN ultimately promotes F-mediated fusion. Thus, it is impossible to understand intermediate fusion states, using standard methods and static observations. Here, we use an on-grid antibody capture method that facilitates examination of fresh, biologically active strains of virus directly from supernatant fluids by cryo-electron tomography and new biological tools that permit capture of the intermediate states in the fusion process. It allows us to visualize the series of events that occur as an authentic HPIV3 viral particle interacts with target receptors and proceeds through intermediate stages from receptor engagement to membrane fusion.